CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
外泌体作为化疗药物的纳米载体：肿瘤学的新时代
英文原题：Exosomes as a Nano-Carrier for Chemotherapeutics: A New Era of Oncology.
查看英文原题
Exosomes as a Nano-Carrier for Chemotherapeutics: A New Era of Oncology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管肿瘤学领域取得了重大进展，癌症仍是全球主要死亡原因之一。癌细胞获得性耐药机制和药物递送效率低，限制了现有化疗药物的疗效。然而，研究已证明纳米药物载体（NDC）可克服这些局限。因此，外泌体成为潜在 NDC 候选物，因为与合成 NDC 相比，外泌体具有更强的器官趋向性、归巢能力、细胞摄取能力和载荷释放能力。此外，外泌体既可作为亲水性化疗药物的 NDC，也可递送疏水性化疗药物。因此，本综述旨在总结无细胞治疗领域的最新进展，介绍外泌体如何参与癌变过程的各个阶段，并讨论如何将这些纳米囊泡开发为化疗药物的纳米载体。
展开英文摘要原文
Despite the considerable advancements in oncology, cancer remains one of the leading causes of death worldwide. Drug resistance mechanisms acquired by cancer cells and inefficient drug delivery limit the therapeutic efficacy of available chemotherapeutics drugs.
However, studies have demonstrated that nano-drug carriers (NDCs) can overcome these limitations. In this sense, exosomes emerge as potential candidates for NDCs. This is because exosomes have better organotropism, homing capacity, cellular uptake, and cargo release ability than synthetic NDCs.
In addition, exosomes can serve as NDCs for both hydrophilic and hydrophobic chemotherapeutic drugs.
Thus, this review aimed to summarize the latest advances in cell-free therapy, describing how the exosomes can contribute to each step of the carcinogenesis process and discussing how these nanosized vesicles could be explored as nano-drug carriers for chemotherapeutics.
论文信息
- 作者
- Araldi RP、Delvalle DA、da Costa VR、Alievi AL、Teixeira MR、Dias Pinto JR、Kerkis I
- 单位
- Genetics Laboratory, Butantan Institute, São Paulo 05503-900, SP, Brazil.Brazil
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cells2023 Aug 25
- 原文标识
- PubMed 37681875 · DOI 10.3390/cells12172144
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →